MX2009006670A - Composicion farmaceutica que usa el aliskiren y el avosentan. - Google Patents
Composicion farmaceutica que usa el aliskiren y el avosentan.Info
- Publication number
- MX2009006670A MX2009006670A MX2009006670A MX2009006670A MX2009006670A MX 2009006670 A MX2009006670 A MX 2009006670A MX 2009006670 A MX2009006670 A MX 2009006670A MX 2009006670 A MX2009006670 A MX 2009006670A MX 2009006670 A MX2009006670 A MX 2009006670A
- Authority
- MX
- Mexico
- Prior art keywords
- avosentan
- aliskiren
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 229960004601 aliskiren Drugs 0.000 title abstract 3
- YBWLTKFZAOSWSM-UHFFFAOYSA-N n-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=CN=CC=2)OC)=C1NS(=O)(=O)C1=CC=C(C)C=N1 YBWLTKFZAOSWSM-UHFFFAOYSA-N 0.000 title abstract 3
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 title abstract 2
- 229950011524 avosentan Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- KLRSDBSKUSSCGU-KRQUFFFQSA-N aliskiren fumarate Chemical compound OC(=O)\C=C\C(O)=O.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC KLRSDBSKUSSCGU-KRQUFFFQSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica y a un método de lograr un efecto terapéutico, el cual incluye, pero no se limita a, el tratamiento de la hipertensión, de enfermedades del riñón o el corazón en un animal, preferiblemente un mamífero, incluyendo un ser humano, usando (i) el 00/alikiren o una sal del mismo, farmacéuticamente aceptable, en combinación con un (ii) SPP3O1 avosentan, o una sal farmacéuticamente aceptable del mismo, e (iii) un portador farmacéuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127175A EP1938812A1 (en) | 2006-12-22 | 2006-12-22 | Pharmaceutical composition using aliskiren and avosentan |
| PCT/EP2007/064404 WO2008077916A1 (en) | 2006-12-22 | 2007-12-21 | Pharmaceutical composition using aliskiren and avosentan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006670A true MX2009006670A (es) | 2009-08-28 |
Family
ID=38038701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006670A MX2009006670A (es) | 2006-12-22 | 2007-12-21 | Composicion farmaceutica que usa el aliskiren y el avosentan. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100173919A1 (es) |
| EP (2) | EP1938812A1 (es) |
| JP (1) | JP2010513414A (es) |
| KR (1) | KR20090117703A (es) |
| CN (1) | CN101652132A (es) |
| AU (1) | AU2007338040A1 (es) |
| BR (1) | BRPI0720376A2 (es) |
| CA (1) | CA2673391A1 (es) |
| MX (1) | MX2009006670A (es) |
| RU (1) | RU2009127858A (es) |
| WO (1) | WO2008077916A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011070049A1 (en) * | 2009-12-09 | 2011-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
| EP2523934A1 (en) * | 2010-02-10 | 2012-11-21 | Ratiopharm GmbH | Salts of aliskiren |
| CN109260164A (zh) * | 2018-10-07 | 2019-01-25 | 威海贯标信息科技有限公司 | 一种阿伏生坦片剂组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US559111A (en) * | 1896-04-28 | treman | ||
| MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| US6417360B1 (en) * | 1999-03-03 | 2002-07-09 | Hoffmann-La Roche Inc. | Heterocyclic sulfonamides |
| CN1930170A (zh) * | 2003-10-23 | 2007-03-14 | 埃科特莱茵药品有限公司 | 二氮杂二环壬烯及四氢吡啶衍生物用作肾素抑制剂 |
-
2006
- 2006-12-22 EP EP06127175A patent/EP1938812A1/en not_active Ceased
-
2007
- 2007-12-21 JP JP2009542084A patent/JP2010513414A/ja active Pending
- 2007-12-21 KR KR1020097015408A patent/KR20090117703A/ko not_active Withdrawn
- 2007-12-21 CN CN200780047033A patent/CN101652132A/zh active Pending
- 2007-12-21 MX MX2009006670A patent/MX2009006670A/es not_active Application Discontinuation
- 2007-12-21 CA CA002673391A patent/CA2673391A1/en not_active Abandoned
- 2007-12-21 US US12/448,467 patent/US20100173919A1/en not_active Abandoned
- 2007-12-21 BR BRPI0720376-4A patent/BRPI0720376A2/pt not_active Application Discontinuation
- 2007-12-21 RU RU2009127858/15A patent/RU2009127858A/ru not_active Application Discontinuation
- 2007-12-21 AU AU2007338040A patent/AU2007338040A1/en not_active Abandoned
- 2007-12-21 WO PCT/EP2007/064404 patent/WO2008077916A1/en not_active Ceased
- 2007-12-21 EP EP07858023A patent/EP2094258A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009127858A (ru) | 2011-01-27 |
| CA2673391A1 (en) | 2008-07-03 |
| CN101652132A (zh) | 2010-02-17 |
| AU2007338040A1 (en) | 2008-07-03 |
| WO2008077916A1 (en) | 2008-07-03 |
| BRPI0720376A2 (pt) | 2013-12-31 |
| JP2010513414A (ja) | 2010-04-30 |
| KR20090117703A (ko) | 2009-11-12 |
| US20100173919A1 (en) | 2010-07-08 |
| EP2094258A1 (en) | 2009-09-02 |
| EP1938812A1 (en) | 2008-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ709704A (en) | Protein formulations and methods of making same | |
| NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| SG135192A1 (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| EA200802412A1 (ru) | Терапевтические комбинации для сопровождающихся болью медицинских состояний | |
| EA201301078A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| IL189546A0 (en) | Therapy for the treatment of disease | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
| WO2006034373A3 (en) | Variants and chemically-modified variants of phenylalanine ammonia-lyase | |
| SE0400184D0 (sv) | New therapeutical use | |
| ATE543492T1 (de) | Behandlung von lungenkrebs | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| EA201070195A1 (ru) | ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРРОЛО [1,2-А]ПИРАЗИН-6-КАРБОКСАМИДОВ И 2,3,4,5-ТЕТРАГИДРОПИРРОЛО [1,2-a][1,4]-ДИАЗЕПИН-7-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
| MX2009006670A (es) | Composicion farmaceutica que usa el aliskiren y el avosentan. | |
| DE602004030048D1 (de) | Ffizienz | |
| TW200635595A (en) | Medicaments for the treatment of prevention of fibrotic diseases | |
| MX2010006443A (es) | TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES. | |
| SI1596879T1 (sl) | Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice | |
| FR2871800B1 (fr) | Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique | |
| WO2007144889A3 (en) | Treatment of neurofibromatosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |